Ivacaftor; Lumacaftor Patent Expiration
Ivacaftor; Lumacaftor is used for treating cystic fibrosis in patients with the F508DEL mutation in the CFTR gene. It was first introduced by Vertex Pharmaceuticals Inc
Ivacaftor; Lumacaftor Patents
Given below is the list of patents protecting Ivacaftor; Lumacaftor, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Orkambi | US8993600 | Modulators of ATP-binding cassette transporters | Dec 11, 2030 | Vertex Pharms Inc |
| Orkambi | US8507534 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | Sep 20, 2030 | Vertex Pharms Inc |
| Orkambi | US8716338 | Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | Sep 20, 2030 | Vertex Pharms Inc |
| Orkambi | US9192606 | Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | Sep 29, 2029 | Vertex Pharms Inc |
| Orkambi | US10646481 | Pharmaceutical composition and administrations thereof | Aug 13, 2029 | Vertex Pharms Inc |
| Orkambi | US11564916 | Pharmaceutical composition and administrations thereof | Aug 13, 2029 | Vertex Pharms Inc |
| Orkambi | US8846718 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid | Jul 02, 2029 | Vertex Pharms Inc |
| Orkambi | US10076513 | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof | Dec 04, 2028 | Vertex Pharms Inc |
| Orkambi | US10597384 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid | Dec 04, 2028 | Vertex Pharms Inc |
| Orkambi | US11052075 | Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof | Dec 04, 2028 | Vertex Pharms Inc |
| Orkambi | US12065432 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid | Dec 04, 2028 | Vertex Pharms Inc |
| Orkambi | US8653103 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid | Dec 04, 2028 | Vertex Pharms Inc |
| Orkambi | US9150552 | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid | Dec 04, 2028 | Vertex Pharms Inc |
| Orkambi | US8324242 | Modulators of ATP-binding cassette transporters | Aug 05, 2027 | Vertex Pharms Inc |
| Orkambi | US7495103 | Modulators of ATP-binding cassette transporters | May 20, 2027 | Vertex Pharms Inc |
| Orkambi | US8410274 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Orkambi | US8754224 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Orkambi | US9670163 | Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Orkambi | US9931334 | Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | Dec 28, 2026 | Vertex Pharms Inc |
| Orkambi | US7973038 | Modulators of ATP-binding cassette transporters | Nov 08, 2026 | Vertex Pharms Inc |
| Orkambi | US8741933 | Modulators of ATP-binding cassette transporters | Nov 08, 2026 | Vertex Pharms Inc |
| Orkambi | US9216969 | Modulators of ATP-binding cassette transporters | Nov 08, 2026 | Vertex Pharms Inc |
| Orkambi | US9216969 | Modulators of ATP-binding cassette transporters | Nov 08, 2026 | Vertex Pharms Inc |
Ivacaftor; Lumacaftor's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List